Vankomisine dirençli enterokok infeksiyonlarının tedavisinde eski ve yeni tedavi seçenekleri

Vankomisine dirençli enterokoklar (VRE) özellikle yoğun bakım ve immünsüprese hastalarda önemli bir hastane kaynaklı infeksiyon nedenidirler. Hem mortalitesi ve maliyeti yüksek hem de tedavisi zor infeksiyonlara neden olurlar. VRE infeksiyonlarında kullanılabilecek en iyi tedavi yöntemi tam olarak belirlenememiştir. Klinik veriler daha çok olgu raporları, hayvan deneyleri ve uzman görüşlerine dayanmaktadır. Bu yazıda VRE infeksiyonlarında kullanılabilecek eski ve yeni tedavi seçenekleri gözden geçirilmiştir.

The old and new treatment options for vancomycin-resistant enterococcal infections

Vancomycin-resistant enterococci are important causes of nosocomial infections occurring in especially critical care or immunocompromised patients. These organisms cause increased mortality and costs, as well as limited treatment options. The optimal therapy for these infections is not well established and clinical data are usually limited to case reports, animal models and sporadic experiences. In this review, the current and possible future therapeutic options for the management of infections caused by vancomycin resistant enterococci were discussed.

PDF

___

1.Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections, Clin Microbiol Infect 2010;16(6):555-62. http://dx.doi.org/10.1111/j.1469-0691.2010. 03214.x/10.1097/INF.0b013e3181e78efc PMid: 20569266
2.Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections, Clin Infect Dis 2012; 54(Suppl 3):S233-8. http://dx.doi.org/10.1093/cid/cir924 PMid: 22431854
3.Arias CA, Panesso D, McGrath DM et al. Genetic basis for in vivo daptomycin resistance in enterococci, N Engl J Med 2011;365(10):892-900. http://dx.doi.org/10.1056/NEJMoa1011138 PMid: 21899450
4.Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data, Clin Infect Dis 2005;41(Suppl 5):S354-67. http://dx.doi.org/10.1086/431676 PMid: 16080073
5.Bagga B, Shenep JL. Management of infections caused by vancomycin-resistant gram-positive bacteria, Pediatr Infect Dis J 2010;29(7):662-4. http://dx.doi.org PMid: 20574403
6.Barrett JF. Recent developments in glycopeptide antibacterials, Curr Opin Investig Drugs 2005;6(8): 781-90. PMid: 16121684
7.Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant Enterococcus with quinupristin/dalfopristin and high-dose ampicillin, Ann Pharmacother 2004;38(6):989-91. http://dx.doi.org/10.1345/aph.1D377 PMid: 15100393
8.Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program, Clin Infect Dis 2003;36(2):159-68. http://dx.doi.org/10.1086/345744 PMid: 12522747
9.Brandt CM, Rouse MS, Laue NW, Stratton CW, Wilson WR, Steckelberg JM. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents, J Infect Dis 1996;173(4):909-13. http://dx.doi.org/10.1093/infdis/173.4.909 PMid: 8603970
10.Centers for Disease Control and Prevention. National Nosocomial Infection Surveillance (NNIS) System: report, data summary from January 1992 through June 2003, issued August 2003, Am J Infect Control 2003;31(8):481-98. http://dx.doi.org/10.1016/j.ajic.2003.09.002 PMid: 14647111
11.Cervera C, Castañeda X, Pericas JM et al. Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci, Int J Antimicrob Agents 2011;38(5):365-70. http://dx.doi.org/10.1016/j.ijantimicag.2010. 11.038 PMid: 21420835
12.Chow JW. Aminoglycoside resistance in enterococci, Clin Infect Dis 2000;31(2):586-9. http://dx.doi.org/10.1086/313949 PMid: 10987725
13.Deshpande LM, Fritsche TR, Moet GJ et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY Antimicrobial Surveillance Program, Diagn Microbiol Infect Dis 2007;58(2):163-70. http://dx.doi.org/10.1016/j.diagmicrobio.2006. 12.022 PMid: 17368801
14.Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam, Clin Infect Dis 2005;41(Suppl 5):S341-53. http://dx.doi.org/10.1086/431675 PMid: 16080072
15.Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin, J Infect 2007;55(3):205-13. http://dx.doi.org/10.1016/j.jinf.2007.05.180 PMid: 17629567
16.Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin- dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia, Clin Infect Dis 2008;46(1):30-6. http://dx.doi.org/10.1086/523588 PMid: 18171210
17.Gavalda J, Len O, Miro JM et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone, Ann Intern Med 2007;146(8):574-9. PMid: 17438316
18.Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression, JAMA 2001; 285(10):1291. http://dx.doi.org/10.1001/jama.285.10.1291 PMid: 11255382
19.Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents, Int J Antimicrob Agents 2005;26(1):43-9. http://dx.doi.org/10.1016/j.ijantimicag.2005.04.007 PMid: 15975769
20.King EA, McCoy D, Desai S, Nyirenda T, Bicking K. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 2011;66(9):2112-8. http://dx.doi.org/10.1093/jac/dkr255 PMid: 21697178
21.Knoll BM, Hellmann M, Kotton CN. Vancomycin- resistant Enterococcus faecium meningitis in adults: Case series and review of the literature, Scand J Infect Dis 2012, Sep 19. http://dx.doi.org/10.3109/00365548.2012.717711 PMid: 22992165
22.Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections, Arch Intern Med 1996;156(22):2579-84. http://dx.doi.org/10.1001/archinte.1996.004402 10097010 PMid: 8951301
23.Lai CC, Wang CY, Chu CC et al. Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009, Eur J Clin Microbiol Infect Dis 2011;30(2):265-71. http://dx.doi.org/10.1007/s10096-010-1081-1 PMid: 20953652
24.Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus, Clin Infect Dis 1998;27(5):1259-65. http://dx.doi.org/10.1086/515002 PMid: 9827280
25.Linden PK. Optimizing therapy for vancomycin- resistant enterococci (VRE), Semin Respir Crit Care Med 2007;28(6):632-45. http://dx.doi.org/10.1055/s-2007-996410 PMid: 18095227
26.Linden PK, Moellering RC Jr, Wood CA et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin, Clin Infect Dis 2001;33(11):1816-23. http://dx.doi.org/10.1086/323899 PMid: 11668430
27.Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin-dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort, J Antimicrob Chemother 1997;39(Suppl A):145-51. http://dx.doi.org/10.1093/jac/39.suppl_1.145 PMid: 9511079
28.Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination, Clin Infect Dis 1998;27(6):1554-6. http://dx.doi.org/10.1086/517755 PMid: 9868693
29.Mizell KN, Carter JE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with linezolid, South Med J 2008;101(5):569- 70. http://dx.doi.org/10.1097/SMJ.0b013e31816c01ef PMid: 18458638
30.Moellering RC, Linden PK, Reinhardt J et al. The efficacy and safety of quinupristin-dalfopristin for the treatment of infections caused by vancomycin- resistant Enterococcus faecium, J Antimicrob Chemother 1999;44(2):251-61. http://dx.doi.org/10.1093/jac/44.2.251 PMid: 10473233
31.Murray BE. Vancomycin-resistant enterococcal infections, N Engl J Med 2000;342(10):710-21. http://dx.doi.org/10.1056/NEJM20000309342100 7 PMid: 10706902
32.National Nosocomial Infections Surveillance (NNIS) System Report. Data summary from January 1992-April 2000, Am J Infect Control 2000;28(6):429-48. http://dx.doi.org/10.1067/mic.2000.110544 PMid: 11114613
33.Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections, Clin Infect Dis 2005;41(Suppl 5):S303-14. http://dx.doi.org/10.1086/431672 PMid: 16080069
34.Pharmacia and Upjohn. Linezolid for the treatment of vancomycin resistant enterococcal infections: A double-blind trial comparing 600 mg linezolid every 12 hours with 200 mg linezolid every 12 hours (study report M/ 1260/0054A), Pharmacia Upjohn Peapack, NJ (1999).
35.Polidori M, Nuccorini A, Tascini C et al. Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline, J Chemother 2011;23(4):240-1. PMid: 21803704
36.Raad I, Hachem R, Hanna H et al. Prospective, randomized study comparing quinupristin- dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections, J Antimicrob Chemother 2004;53(4):646-9. http://dx.doi.org/10.1093/jac/dkh144 PMid: 14998986
37.Ricaurte JC, Boucher HW, Turett GS, Moellering RC, Labombardi VJ, Kislak JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia, Clin Microbiol Infect 2001;7(1):17-21. http://dx.doi.org/10.1046/j.1469-0691.2001.00189.x PMid: 11284938
38.Rosin C, Bernsmeier C, Entenza JM et al. Daptomycin for highly resistant Enterococcus faecium infection, Swiss Med Wkly 2012;142: w13603. http://dx.doi.org/10.4414/smw.2012.13603 PMid:22736040
39.Sakoulas G, Golan Y, Lamp KC et al. Daptomycin in the treatment of bacteremia, Am J Med 2007;120(10 Suppl 1):S21-7. http://dx.doi.org/10.1016/j.amjmed.2007.07.012 PMid: 17904947
40.Scheetz MH, Knechtel SA, Malczynski M et al. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption, Antimicrob Agents Chemother 2008; 52(6):2256-9. http://dx.doi.org/10.1128/AAC.00070-08 PMid: 18391028
41.Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review, Clin Infect Dis 1992;15(2):302-6. http://dx.doi.org/10.1093/clinids/15.2.302 PMid: 1387808
42.Smith DL, Johnson JA, Harris AD et al. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium, Lancet Infect Dis 2003;3(4):241-9. http://dx.doi.org/10.1016/S1473-3099(03)00581-4 PMid: 12679267
43.Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature, Clin Infect Dis 2005; 41(8):1134-42. http://dx.doi.org/10.1086/444459 PMid: 16163631
44.Tsai HY, Liao CH, Chen YH et al. Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) Study, 2006 to 2010, Antimicrob Agents Chemother 2012;56(6):3402-5. http://dx.doi.org/10.1128/AAC.00533-12 PMid: 22491684
45.Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci, Lancet 1988; 1(8575-6):57-8. http://dx.doi.org/10.1016/S0140-6736(88)91037-9 PMid: 2891921
46.Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci, Expert Opin Pharmacother 2009;10(5):785-96. http://dx.doi.org/10.1517/14656560902811811 PMid: 19351228
47.Zhanel GG, Hoban DJ, Karlowsky JA. Nitrofurantoin is active against vancomycin- resistant enterococci, Antimicrob Agents Chemother 2001;45(1):324-6. http://dx.doi.org/10.1128/AAC.45.1.324-326.2001 PMid: 11120989